Immune science

Older adults likely remain at higher risk for COVID-19 − particularly infections caused by variants of concern − even after vaccination

In a recent CITF-funded pre-print, therefore not yet peer-reviewed, Drs. Mark Brockman and Zabrina Brumme from Simon Fraser University and Dr. Marc Romney from the University of British Columbia studied immune responses following COVID-19 vaccination in over 150 adults aged 24-98 years. They found that although two doses of the mRNA vaccines provide excellent [...]

2021-09-13T23:31:41-04:00September 14, 2021|Immune science|

COVID-19 vaccines generate detectable specific antibodies in saliva

It is known that existing COVID-19 vaccines trigger the production of neutralizing antibodies in blood. However, since SARS-CoV-2 first enters the body via the upper respiratory tract, if antibodies were located in this area, they could potentially start fighting the virus immediately. A recent preprint, not yet peer-reviewed, examines whether COVID-19 vaccines induce antibodies [...]

2021-08-17T11:55:38-04:00August 17, 2021|Immune science|

Poorer neighbourhoods and racialized communities continue to lag behind in vaccine coverage: latest Canadian Blood Services results

The gap between the rates of COVID-19 infection and vaccination among racialized and non-racialized Canadians continues to exist, as does the gap between Canadians from lower- and higher-income neighbourhoods. The CITF-funded Canadian Blood Services Serosurveillance Study has released its latest report for the month of May 2021. While the latest data show that the [...]

2021-08-10T16:01:33-04:00August 10, 2021|Immune science|

Previous infection with common cold seasonal coronavirus may protect some from severe COVID-19

Nearly everyone has been exposed to the highly prevalent seasonal coronaviruses responsible for the common cold. But could this exposure induce antibodies that also recognize certain proteins of the SARS-CoV-2 virus? A CITF-funded study led by University of Ottawa researcher Dr. Marc-André Langlois, questioned if these antibodies could influence COVID-19 disease severity. In this [...]

2021-07-19T17:08:26-04:00July 20, 2021|Immune science|

Early results from a national study confirm antibody levels are stronger after receiving two doses

Initial preliminary results from the Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose.

2021-06-23T09:12:41-04:00June 23, 2021|Immune science, Media Releases|

Immunity to SARS-CoV-2 persists for 9 months

The mechanisms of immune protection to SARS-CoV-2 are still unclear and researchers around the world are attempting to address this critical question. In a preprint, not yet peer-reviewed, Dr. Tania Watts from the University of Toronto, unravels the characteristics and extent of B and T cell responses of our immune system after recovery from [...]

2021-06-22T11:57:49-04:00June 22, 2021|Immune science|

Recovered COVID-19 individuals can have SARS-CoV-2 antibodies for at least 6 months

In a recent publication in Viruses, Dr. Ishac Nazy from McMaster University finds that SARS-CoV-2 antibodies against the spike and receptor binding domain are present for at least six months, confirming similar research by other CITF-funded researchers. In this publication, Dr. Nazy characterizes SARS-CoV-2 antibodies in recovered COVID-19 patients. This study was funded in [...]

2021-05-03T16:46:23-04:00May 4, 2021|Immune science|

Changes in immune cells in COVID patients could be a sign suggesting an unfavorable outcome

In a publication in the Journal of Clinical Investigation, Drs. Daniel Kaufmann and Andrés Finzi from Université de Montréal and collaborators, found that patients with acute SARS-CoV-2 infection have altered immune responses affecting the severity of symptoms and mortality. These findings may help clinicians identify patients at risk of unfavourable outcomes and shed light [...]

2021-04-26T15:37:27-04:00April 27, 2021|Immune science|

Immune cell analysis reveals that the amount of SARS-CoV-2 in the blood is a strong predictor of mortality

As SARS-CoV-2 continues to cause worldwide mortality, it has become increasingly important to define molecular markers that can identify individuals at risk of developing severe COVID-19, and even death. This could help in determining early preventive measures for improved patient outcomes. In a recent pre-print and therefore not yet peer-reviewed, CITF-funded researchers Drs. Daniel [...]

2021-03-29T20:47:05-04:00March 30, 2021|Immune science|
Go to Top